4,901 trials
Diabetic Kidney Disease
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Selonsertib and Its Metabolite GS-607509 — 3316.1; 3266.7; 2962.1; 2835.3 hr*ng/mL
Lung Cancer · Breast Cancer · Prostate Cancer
Primary: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) — 3; 14; 17 Participants
Schizophrenia
Primary: OPC-14597 Plasma Concentration 672 Hours Postdose Following Multiple Administration of OPC-14597 IMD Injections — 91.9; 141; 171; 198 ng/mL
Healthy Volunteers
Primary: Steady State Concentrations of TFV-DP for Different Dosing Patterns of Descovy — 657; 1451; 2381 fmol/punch
Cancer of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Cancer of the Stomach
Primary: Maximum Tolerated Dose of Vandetanib — 100 milligrams
Respiratory Tract Disorders
Primary: Peak Drug Concentration (Cmax) After Single Dose of NAC — 83.30 µg/mL
Lung Cancer · Metastatic Cancer
Primary: Number of Participants With Dose Limiting Toxicities and Maximum Tolerated Dose (MTD) — 0; 2; 0; 0 Participants
Chronic Obstructive Pulmonary Disease
Primary: Maximum Plasma Concentration (Cmax) - Budesonide — 459.308; 224.298 pg/mL
Head and Neck Cancer · Squamous Cell Carcinoma · Oral Cavity Cancer
Primary: Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided. — 57…
Rheumatoid Arthritis
Primary: Pharmacokinetic (PK) Parameter: AUClast of Filgotinib — 2389.3; 1981.9 h*ng/mL
Marburg Virus Disease
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-Marburg Vaccine Administration — 9; 4; 13; 10 Participants
Rectal Cancer
Primary: The Number of Participants Experiencing Dose Limiting Toxicities (DLT) — 0; 0; 0 Participants
Infection by Streptococcus Group B
Primary: Part A Number of Participants With Treatment Emergent Adverse Events — 6; 5; 5; 6 participants
Venous Thromboembolism · Traumatic Brain Injury
Primary: Percentage of Participants With Worsening TBI Hemorrhage — 5.9; 3.6 percentage of participants
Neoplasms, Breast
Primary: Percentage of Participants With Tumor Response Measured by Breast MRI — 90.5 Percentage of participants